PEGINTERFERON相关论文
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterfer
...
我国HBeAg阴性慢性乙型肝炎(CHB)占CHB患者的30％ ～ 40％,且有增长趋势[1];以基因B、C型为主.HBeAg阴性CHB患者ALT持续或反复异常,肝组......
目的以标准剂量聚乙二醇干扰素α-2a（Peg-IFN α-2a）作为阳性药对照，评价长效干扰素Peg-IFN α-2b （Y型，40 kD）注射液（180 μg/周）治疗HBeA......
BACKGROUND:?The relationship between cytokines and responses to peginterferonα-2a treatment in chronic hepatitis B pati......
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy dur
Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) is well known to be associa......
AIM:To study the relation between hepatitis C virus (HCV) genotype 4 and microalbuminuria and renal impairment in relati......
Individualized hepatocellular carcinoma risk: The challenges for designing successful chemopreventio
Hepatocellular carcinoma (HCC) develops in the context of environmental risk factors like chronic viral hepatitis, diabe......
目的探讨IL28B基因多态性（SNP）与聚乙二醇干扰素ɑ（Peg IFNα）24周疗程治疗HBe Ag阳性慢性乙型肝炎（CHB）疗效的相关性。方法采集398例接......
目的探讨替诺福韦酯联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎(CHB)临床疗效及影响因素。方法 120例CHB患者,根据治疗方式不同分为......
BACKGROUND: The relationship between cytokines and responses to peginterferon α-2a treatment in chronic hepatitis B pat......
Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antiviral
BACKGROUND: The availability of novel direct-acting antivirals(DAAs) represents a new era of curative hepatitis C virus(......
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy dur
Peginterferon and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) is well known to be associa......
瞄准：估计三倍的治疗(peginte-rferon 或高剂量标准干扰素，正 ribavirin 和 amantadine ) 的功效在非应答者到优先的联合治疗。方法：1......
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterfer
瞄准：估计临床，生物化学并且 virological 在长期的丙肝(CHC ) 的长期的结果有在加 ribavirin 的 peginterferon (PEG-IFN ) 以后的......
AIM: To study the differential protein profile in serum of hepatitis B patients.METHODS: Serum samples were obtained fro......
Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepati
AIM: To evaluate the impact of sociodemographic/clinical factors on early virological response (EVR) to pegin-terferon/r......
AIM:To investigate the occurrence and severity of pruritus in chronic hepatitis C patients treated with or without inter......
目的观察聚乙二醇干扰素α-2a、利巴韦林联合解毒升白颗粒治疗慢丙型肝炎患者的临床疗效以及不良反应。方法选择有抗病毒应用指征......
目的：观察扶正化瘀胶囊对丙型肝炎患者肝纤维化的改善作用。方法：入组65例丙型肝炎肝纤维化患者,按随机数字表法分为治疗组和对照组,......
Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy
AIM:To analyzed the association between inosine triphosphatase(ITPA)(rs1127354) genotypes and sustained virological resp......
AIM:To investigate the possibility of shortening the duration of peginterferon(Peg-IFN)plus ribavirin(RBV) combination t......
Treatment of chronic hepatitis B(CHB) has markedly improved in the last 15 years due to the availability of direct antiv......
Hepatitis B virus （HBV） persistently infects approximately350 million people, and approximately 600000 liverrelateddeaths ......
AIM To evaluate addition of boceprevir to peginterferon/ribavirin （PR） in Russian patients with chronichepatitis C virus （H......
目的：探讨慢性丙型肝炎基因1型患者经聚乙二醇干扰素α-2a（PEG-INFα-2a）联合利巴韦林（RBV）治疗后快速病毒学应答（RVR）、早期完全病毒学应......
目的观察阿德福韦酯与聚乙二醇干扰素α-2a联合用药对服用拉米夫定治疗后出现YMDD变异的慢性乙肝患者的疗效及安全性分析。方法选......
Hepatitis C virus(HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from H......
AIM: To study the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin i......
Before the advent of direct acting antiviral agents （DAAs）ribavirin, associated to pegylated-interferon playeda crucial ro......
Peginterferon is a key drug used to treat chronic viral hepatitis that is known for causing various side effects.Side ef......
